Conexxence Injection
Product Images NDC 65219-668

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Conexxence (NDC 65219-668). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tra1a 0001 01)

An instructional diagram showing a CONEXXENCE (Denosumab) 60 mg/mL injection syringe before and after use. The syringe is labeled with components including the needle cap, clear needle guard, liquid-filled syringe barrel, plunger, and needle guard spring. After use, the needle is covered by the extended needle guard spring for safety.*

FDA Label Image

Figure A (Tra1a 0001 02)

An instructional illustration showing the removal of the protective cap from a prefilled syringe with a purple arrow indicating the direction to pull. The syringe appears to be used for subcutaneous injection, consistent with the CONEXXENCE (Denosumab) injection dosage form.*

FDA Label Image

Figure B (Tra1a 0001 03)

Illustration depicting recommended subcutaneous injection sites for CONEXXENCE (Denosumab) 60 mg/mL injection. Front view highlights abdomen and upper thighs in purple as injection areas; rear view shows upper arms similarly marked for subcutaneous administration.*

FDA Label Image

Figure C (Tra1a 0001 04)

An instructional illustration showing the administration of a subcutaneous injection with a syringe. The image focuses on a hand holding the syringe labeled with pink markings, inserting the needle into the skin of a forearm. A magnified inset highlights the syringe's finger guard mechanism. A purple arrow indicates the action of injection.*

FDA Label Image

Figure D (Tra1a 0001 05)

An instructional illustration demonstrating the subcutaneous administration of CONEXXENCE 60 mg/mL injection. It shows a hand preparing to inject the medication into the skin of an arm, with an inset highlighting the CONEXXENCE vial or syringe label. An arrow indicates the direction for injection.*

FDA Label Image

Figure (Tra1a 0001 06)

A line graph depicting patient hip fracture incidence (%) over a study period of 36 months. The graph compares placebo and Denosumab treatment groups, showing lower fracture incidence in the Denosumab group throughout the study.*

FDA Label Image

Figure (Tra1a 0001 07)

CONEXXENCE 60 mg/mL denosumab injection for subcutaneous use, supplied in a single-dose 1 mL vial. The label includes manufacturer information: Fresenius Kabi USA, LLC. The vial label features standard drug product details including the proprietary name, nonproprietary name, concentration, and route of administration.*

FDA Label Image

Principal Display Panel – 60 mg/ml Carton Label (Tra1a 0001 08)

The packaging label for Conexxence (denosumab-bnht) injection, 60 mg/mL, for subcutaneous use. It features a single-dose prefilled syringe with instructions to discard unused portions. The carton includes one syringe, prescribing information, and a medication guide. Manufactured by Fresenius Kabi USA, LLC, the label emphasizes sterile solution with no preservative and advises administration by a healthcare provider.*

FDA Label Image

Principal Display Panel – 60 mg/ml Syringe Label (Tra1a 0001 09)

Label for CONEXXENCE denosumab-bnht injection, 60 mg/mL strength, intended for subcutaneous use. The label shows it is Rx only, manufactured by Fresenius Kabi USA, LLC, with a U.S. license number 2146. It includes an NDC number 65219-668-01 and has a barcode. Lot and expiration date fields are present but not filled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.